Tamoxifen is excreted slowly in the faeces, mainly as conjugates. Each ml of the sterile solution contains 20 mg of plerixafor. Oct 04, 2019 carfilzomib is a crystalline substance with a molecular weight of 719. Twice weekly 2056 mgm2 regimen by 30minute infusion. Infuse over 10 or 30minutes depending on the kyprolis dose regimen see dosage and administration 2. Revlimid lenalidomide is a prescription medicine, used to treat adults with multiple myeloma mm in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation a type of stem cell transplant that uses your own stem cells. Easytoread drug name and dosage strength to aid in identifying the right product. Dacogen decitabine for injection description dacogen decitabine for injection contains decitabine 5aza2deoxycytidine, an analogue of the natural nucleoside 2. Kyprolis carfilzomib for injection, for intravenous use. Carfilzomib is given via intravenous route on two consecutive days per week, depending on the cycle of therapy, so access to an infusion clinic is necessary.
Carfilzomib is administered at a dose of 20 mgm 2 in cycle 1 and, if tolerated, should be increased to 27 mgm 2 beginning in cycle 2 and continuing in subsequent cycles. Carfilzomib is an irreversible inhibitor of the 20s core of the 26s. Components lenalidomide and dexamethasone are both oral, yet only taken on. Darzalex has extensive clinical experience in multiple myeloma 1,2. Carfilzomib is in a class of medications called proteasome inhibitors. The attached package contains background information prepared by the food and drug administration fda for the panel members of the advisory committee. Kyprolis carfilzomib for relapsed multiple myeloma treatment. It is freely soluble in water, soluble in methanol, and slightly soluble in ethanol.
Carfilzomib is associated with a low rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal. Kyprolis carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Libtayo, a programmed death receptor1 pd1 inhibitor, is the first and only fdaapproved therapy indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation 1. In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy 2. Incidence and management of adverse events in patients with. Carfilzomib and daratumumabnaive patients n 85 received carfilzomib weekly on days 1, 8, and 15 of each 28day cycle 20 mgm 2 initial dose, escalated to 70 mgm 2 thereafter and dexamethasone 40 mgwk. Auc is doseproportional over the dose range of 2036 mgm 2.
If needed, give an additional 250 ml to 500 ml of intravenous fluids following kyprolis administration. Highlights of prescribing information these highlights do not include all the information needed to use cancidas safely and effectively. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Dexamethasone 20 mg is taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28day cycle. Fda briefing document oncologic drugs advisory committee. Bar codes included on the vial and carton for ease of scanning. Mozobil plerixafor injection, for subcutaneous use. Of these, 10 patients received the first daratumumab dose as a single infusion 16 mgkg, day 1 cycle 1, and 75 patients received a. See important safety information and prescribing information. Kyprolis is indicated as a single agent for the treatment of patients with relapsed or. Carfilzomib is administered as a 210minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28day cycle at a starting dose of 20 mgm 2 for cycle 1 and a target dose of 27 mgm 2 thereafter. Oncology related including new drugs, antagonists, etc. Carfilzomib is an irreversible proteasome inhibitor and antineoplastic agent that is used in treatment of refractory multiple myeloma. Highlightsof prescribing information kyprolis safely and.
Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy see clinical studies 14. Infuse over 10 or 30 minutes depending on the kyprolis dose regimen. Administration kyprolis can be administered in a 50ml or 100ml intravenous bag of 5% dextrose injection, usp. Jun 01, 2015 cisplatin injection is a clear, lightyellow, sterile aqueous solution available in amber vials containing 1 mgml of cisplatin. Monitor for fever and other signs of infection and treat promptly. In combination with dexamethasone or with lenalidomide plus. This will allow quick identification of new safety information. Carfilzomib is supplied in singleuse vials containing 60 mg sterile lyophilized powder, which should be reconstituted with 29 ml sterile water onyx pharmaceuticals, 2012. Kyprolis carfilzomib is a treatment option for people who have already received 1 or more previous treatments for relapsed multiple myeloma. October 30, 2019 page 3 of 3 kyprolis carfilzomib package insert applicable procedure codes j9047 injection, carfilzomib, 1 mg applicable diagnosis codes icd10 icd10 description c90. Kyprolis, inncarfilzomib european medicines agency. Vials of vinblastine sulfate for injection usp contain 10 mg. Kyprolis carfilzomib rationale for inclusion in pa.
The reconstituted solution contains carfilzomib at a concentration of 2 mgml. Kyprolis carfilzomib is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. Cisplatin injection is a clear, lightyellow, sterile aqueous solution available in amber vials containing 1 mgml of cisplatin. Kyprolis carfilzomib rationale for inclusion in pa program. The nccn compendium is a derivative work of the nccn guidelines. Carfilzomib is a crystalline substance with a molecular weight of 719. Highlights of prescribing information these highlights do not. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of. Ninlaro ixazomib capsules, for oral use hepatotoxicity. Get emergency medical help if you have signs of an allergic reaction. Kyprolis carfilzomib for relapsed or refractory multiple. Carfilzomib is associated with a low rate of serum.
The recommended dose of carfilzomib for the first cycle is. Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. The small molecule cytotoxin, dm1, is a microtubule inhibitor. Tamoxifen appears to undergo enterohepatic circulation ndesmethyltamoxifen has a.
October 30, 2019 page 3 of 3 kyprolis carfilzomib package insert applicable procedure codes j9047 injection, carfilzomib, 1 mg applicable diagnosis. Unopened vials of kyprolis are stable until the date indicated on the package when stored in the original package at 2c to 8c 36f to 46f. Highlightsof prescribing information these highlights do not include all the information needed to use kyprolis safely and effectively. It is sometimes given with other medicines when treating relapsed multiple myeloma. Carfilzomib kyprolis drug monograph va pbm services. Estimate based on projected patients, calculations on demand, and duration of treatment. Daratumumab plus carfilzomib and dexamethasone in patients. Product information on treatment with velcade and resources to help you understand and manage your condition. Carfilzomib was initially fdaapproved in 2012 as monotherapy in myeloma. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 10 mg, 30 mg or 60 mg vial. Mozobil plerixafor injection is a sterile, preservativefree, clear, colorless to paleyellow, isotonic solution for subcutaneous injection.
Interrupt empliciti elotuzumab for grade 2 or higher and permanently discontinue for severe infusion reaction. Carfilzomib is practically insoluble in water and very. You can get the information about thalomid and the thalomid rems program on the internet at. Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat. The fda also approved kyprolis as a single agent for the treatment of patients with relapsed or refractory myeloma who have received. Highlights of prescribing information these highlights. Upon binding to subdomain iv of the her2 receptor, adotrastuzumab emtansine undergoes. Carfilzomib, kyprolis, multiple myeloma, proteasome inhibitor, px171003a1. Carfilzomib injection is used alone and in combination with dexamethasone or lenalidomide revlimid and dexamethasone to treat people with multiple myeloma a type of cancer of the bone marrow who have already been treated with other medications. Unopened vials of carfilzomib are stable until the date indicated on the package when stored in the original package. The recommended hydration includes both oral fluids 30 ml per kg at least 48 hours before cycle 1, day 1 and intravenous fluids 250 ml to 500 ml of appropriate intravenous fluid prior to each dose in cycle 1. Cefazolin for injection, usp sagent pharmaceuticals.
Darzalex faspro is a prescription medicine used to treat adult patients with multiple myeloma. May 08, 2014 carfilzomib, a selective proteasome inhibitor approved in the usa in 2012, is a single agent for relapsed and refractory multiple myeloma. Aug 01, 2019 carfilzomib was administered weekly on days 1, 8, and 15 of each 28day cycle as a 30minute infusion prior to daratumumab on days when both were administered. Thalomid rems program, approved by the food and drug administration. The antibody is the humanized antiher2 igg1, trastuzumab. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Kyprolis carfilzomib is a proteasome inhibitor indicated for the treatment. Worldwide since approval 2 1530 patients treated with darzalex in clinical trials 1. Teflaro ceftaroline fosamil is indicated in adult and pediatric patients at least 34 weeks gestational age and 12 days postnatal age and older for the treatment of acute bacterial skin and skin structure infections absssi caused by susceptible isolates of the following grampositive and gramnegative microorganisms. Carfilzomib pharmacokinetics absorption bioavailability. Kyprolis carfilzomib for injection, for intravenous use initial u. Jakafi is indicated for treatment of intermediate or highrisk myelofibrosis mf, including primary mf, postpolycythemia vera mf and postessential thrombocythemia mf in adults.
Adotrastuzumab emtansine is a her2targeted antibodydrug conjugate. Official hcp website darzalex faspro daratumumab and. The proteasome is a system within the cells that breaks down proteins when they are damaged or no longer. Refer to the dexamethasone prescribing information for other information on that product. The clinical formulation is supplied in a sterile form for intravenous use only. Kyprolis is indicated for the treatment of patients with multiple myeloma who have. Carfilzomib vials contain no antimicrobial preservatives and are intended only for single use.
388 171 1443 1492 147 188 306 462 903 1225 794 1579 1427 334 576 431 115 1179 1551 863 630 60 154 256 1182 739 85 626 674 744 571